A recent study from Yale University has uncovered a surprising mechanism by which GLP-1 therapies, like Ozempic, support sustained weight loss. Contrary to previous beliefs that these medications solely suppress appetite, the research indicates they also activate hunger neurons,…
This article explores the psychological complexities behind maintaining healthy eating habits, highlighting the internal conflicts individuals face when trying to adhere to dietar…
A recent study published in JAMA Network Open found that a low-fat vegan diet can lead to weight loss comparable to the injectable medication semaglutide over a 16-week period. Pa…
As the yogurt aisle becomes increasingly competitive with high-protein options, experts warn consumers to consider more than just protein content, especially those using GLP-1 med…
GLP-1 medications, including Ozempic and Wegovy, are linked to unexpected side effects such as hair loss. This occurs primarily due to a condition called telogen effluvium, trigge…
A recent study published in Diabetes, Obesity and Metabolism indicates that GLP-1 drugs, commonly used to treat type 2 diabetes and obesity, may also lower the risk of age-related…
A recent study funded by the NIH has uncovered how newer oral GLP-1 drugs, including orforglipron and danuglipron, affect the brain's reward circuits in mice, potentially reducing…
Dr. Gabrielle Lyon, a pioneer in muscle-centric medicine, argues that skeletal muscle is crucial for metabolic health and longevity, challenging conventional weight-loss wisdom. H…
Researchers at Stanford Medicine have discovered a naturally occurring peptide, BRP, that may suppress appetite through a targeted pathway, potentially offering a new approach to…
Stanford Medicine researchers have discovered a naturally occurring molecule named BRP that may suppress appetite and reduce body weight similarly to semaglutide, the active ingre…
A recent study has found that GLP-1 drugs like Wegovy and Ozempic, used for obesity and type 2 diabetes, may be associated with a higher risk of hair loss, particularly non-scarri…
A recent survey by ZipHealth explores the complexities of disclosing GLP-1 medication use, such as Ozempic, in dating scenarios. While many users reported positive dating experien…
Beauty industry leaders are ramping up efforts to develop treatments specifically designed for those experiencing facial volume loss, promising to redefine the standards of beauty…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…
In a stunning twist of regulatory fate, the FDA has issued new hair-raising guidelines for users of GLP-1 drugs like Ozempic and Mounjaro, warning of a 37-68% increased risk of ha…